AR and prostate adenocarcinoma: Indeed, most cases of neuroendocrine prostate cancer, or anaplastic prostate cancer arise after hormone therapy [18] and the evolution of an AR-neuroendocrine phenotype from prostate adenocarcinoma is a proposed mechanism of anti-androgen resistance [19,20].